Fertility and Sterility
Volume 90, Issue 4 , Pages 1144-1148 , October 2008

Clinical, endocrine, and metabolic effects of acarbose, a α-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome

References 

  1. Franks S. Polycystic ovary syndrome. N Eng J Med. 1995;333:853–861
  2. Nestler JE. Role of the hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome and its clinical implications. Semin Reprod Endocrinol. 1997;15:111–122
  3. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Endocrinol Metab. 1996;81:3299–3306
  4. Ehrmann DA. Insulin-lowering therapeutic modalities for poly-cystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28:423–438
  5. Nestler JE, Jacubowicz D. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335:617–623
  6. Legro RS, Kunselman AR, Donson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169
  7. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647–654
  8. Geisthovel F, Frorath B, Brabant G. Acarbose reduces elevated testosterone serum concentrations in hyperinsuliaemic premenopausal women: a pilot study. Hum Reprod. 1996;11:2377–2381
  9. Ciotta L, Calogero AE, Farina M, De Leo V, La Marca A, Cianci A. Clinical, endocrine and metabolic effect of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod. 2001;16:2066–2072
  10. Sonmez AS, Yasar L, Savan K, Koc S, Ozcan J, Toklar A, et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod. 2005;20:175–179
  11. Laube H. Acarbose: an update therapeutic use in diabetes treatment. Clin Drug Invest. 2000;22:141–156
  12. Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet. 1996;30:94–106
  13. Penna IA, Canella PR, Reis RM, Silva De Sa MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod. 2005;20:2396–2401
  14. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab. 1996;81:952–960
  15. Martikainen H, Salmela P, Nuojua-Huttunen S, Perala J, Leinonen S, Knip M, et al. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertil Steril. 1996;66:564–570
  16. Meirow D, Yossipowitch O, Rosler A. Insulin resistant and nonresistant polycystic ovary syndrome represent two separate clinical and endocrinologic subgroups. Hum Reprod. 1995;10:1951–1956

PII: S0015-0282(07)02963-9

doi: 10.1016/j.fertnstert.2007.07.1326

Fertility and Sterility
Volume 90, Issue 4 , Pages 1144-1148 , October 2008

Article Tools